Metastatic Suppressor Genes Inactivated by Aberrant Methylation in Gastric Cancer

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2007 Oct 30

PMID 17963294

Citations 12

Authors

Jian-Feng Wang

Dong-Qiu Dai

Affiliations

Soon will be listed here.

Abstract

Aim: To screen out the differentially methylated DNA sequences between gastric primary tumor and metastatic lymph nodes, test the methylation difference of gene PTPRG between primary gastric tumor and metastatic lymph nodes, and test the regulatory function of 5-aza-2'-deoxycytidine which is an agent with suppression on methylation and the level of methylation in gastric cancer cell line.

Methods: Methylated DNA sequences in genome were enriched with methylated CpG islands amplification (MCA) to undergo representational difference analysis (RDA), with MCA production of metastatic lymph nodes as tester and that of primary tumor as driver. The obtained differentially methylated fragments were cloned and sequenced to acquire the base sequence, which was analyzed with bioinformatics. With methylation-specific PCR (MSP) and RT-PCR, methylation difference of gene PTPRG was detected between primary tumor and metastatic lymph nodes in 36 cases of gastric cancer. Methylation of gene PTPRG and its regulated expression were observed in gastric cancer cell line before and after being treated with methylation-suppressive agent.

Results: Nineteen differentially methylated sequences were obtained and located at 5' end, exons, introns and 3' end, in which KL59 was observed to be located at 9p21 as the first exon of gene p16 and KL22 to be located at promoter region of PRPRG. KL22, as the probes, was hybridized with driver, tester and 3-round RDA products respectively with all positive signals except with the driver. Significant difference was observed in both methylation rate of gene PTPRG and PTPRG mRNA expression rate between primary tumor and metastatic lymph nodes. Demethylation of gene PTPRG, with recovered expression of PTPRG mRNA, was observed after gastric cancer cell line being treated with methylation-suppressive agent.

Conclusion: Difference exists in DNA methylation between primary tumor and metastatic lymph nodes of gastric cancer, with MCA-RDA as one of the good analytical methods. Significant difference exists in methylation of gene PTPRG between primary tumor and metastatic lymph nodes of gastric cancer. Methylation level in gastric cancer cell line can be decreased by 5-aza-2'-deoxycytidine, which is the methylation-suppressive agent, with PTPRG expression being recovered.

Citing Articles

Aberrant DNA methylation of PTPRG as one possible mechanism of its under-expression in CML patients in the State of Qatar.

Ismail M, Samara M, Al Sayab A, Alsharshani M, Yassin M, Varadharaj G Mol Genet Genomic Med. 2020; 8(10):e1319.

PMID: 32700424 PMC: 7549574. DOI: 10.1002/mgg3.1319.

Protein tyrosine phosphatases: promising targets in pancreatic ductal adenocarcinoma.

Ruckert M, Andrade P, Santos V, Silveira V Cell Mol Life Sci. 2019; 76(13):2571-2592.

PMID: 30982078 PMC: 11105579. DOI: 10.1007/s00018-019-03095-4.

Tumor suppressor SET9 guides the epigenetic plasticity of breast cancer cells and serves as an early-stage biomarker for predicting metastasis.

Montenegro M, Sanchez-Del-Campo L, Gonzalez-Guerrero R, Martinez-Barba E, Pinero-Madrona A, Cabezas-Herrera J Oncogene. 2016; 35(47):6143-6152.

PMID: 27132511 DOI: 10.1038/onc.2016.154.

Prognostic implication of PTPRH hypomethylation in non-small cell lung cancer.

Sato T, Soejima K, Arai E, Hamamoto J, Yasuda H, Arai D Oncol Rep. 2015; 34(3):1137-45.

PMID: 26134684 PMC: 4530927. DOI: 10.3892/or.2015.4082.

PTPRG suppresses tumor growth and invasion via inhibition of Akt signaling in nasopharyngeal carcinoma.

Cheung A, Ip J, Chu A, Cheng Y, Leong M, Ko J Oncotarget. 2015; 6(15):13434-47.

PMID: 25970784 PMC: 4537025. DOI: 10.18632/oncotarget.3876.

References

Liu L, Xiao W, Liu W . Effect of 5-Aza-2'-deoxycytidine on the P16 tumor suppressor gene in hepatocellular carcinoma cell line HepG2. World J Gastroenterol. 2002; 7(1):131-5. PMC: 4688690. DOI: 10.3748/wjg.v7.i1.131. View

Lisitsyn N, Wigler M . Cloning the differences between two complex genomes. Science. 1993; 259(5097):946-51. DOI: 10.1126/science.8438152. View

Costello J, Fruhwald M, Smiraglia D, Rush L, Robertson G, Gao X . Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet. 2000; 24(2):132-8. DOI: 10.1038/72785. View

Herman J, Graff J, Myohanen S, Nelkin B, Baylin S . Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996; 93(18):9821-6. PMC: 38513. DOI: 10.1073/pnas.93.18.9821. View

Teodoridis J, Hall J, Marsh S, Kannall H, Smyth C, Curto J . CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res. 2005; 65(19):8961-7. DOI: 10.1158/0008-5472.CAN-05-1187. View

Catteau A, Harris W, Xu C, Solomon E . Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene. 1999; 18(11):1957-65. DOI: 10.1038/sj.onc.1202509. View

Choi I, Wu T . Epigenetic alterations in gastric carcinogenesis. Cell Res. 2005; 15(4):247-54. DOI: 10.1038/sj.cr.7290293. View

Wang Z, Shen D, Parsons D, Bardelli A, Sager J, Szabo S . Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science. 2004; 304(5674):1164-6. DOI: 10.1126/science.1096096. View

Motiwala T, Ghoshal K, Das A, Majumder S, Weichenhan D, Wu Y . Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas. Oncogene. 2003; 22(41):6319-31. PMC: 3020652. DOI: 10.1038/sj.onc.1206750. View

10.

Toyota M, Itoh F, Imai K . DNA methylation and gastrointestinal malignancies: functional consequences and clinical implications. J Gastroenterol. 2000; 35(10):727-34. DOI: 10.1007/s005350070030. View

11.

Deng G, Chen A, Hong J, Chae H, Kim Y . Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res. 1999; 59(9):2029-33. View

12.

Kholodnyuk I, Szeles A, Yang Y, Klein G, Imreh S . Inactivation of the human fragile histidine triad gene at 3p14.2 in monochromosomal human/mouse microcell hybrid-derived severe combined immunodeficient mouse tumors. Cancer Res. 2001; 60(24):7119-25. View

13.

Robertson K, Jones P . DNA methylation: past, present and future directions. Carcinogenesis. 2000; 21(3):461-7. DOI: 10.1093/carcin/21.3.461. View

14.

Issa J . Epigenetic variation and human disease. J Nutr. 2002; 132(8 Suppl):2388S-2392S. DOI: 10.1093/jn/132.8.2388S. View

15.

Rashid A, Shen L, Morris J, Issa J, Hamilton S . CpG island methylation in colorectal adenomas. Am J Pathol. 2001; 159(3):1129-35. PMC: 1850474. DOI: 10.1016/S0002-9440(10)61789-0. View

16.

Fang J, Lu J, Chen Y, Yang L . Effects of DNA methylation on expression of tumor suppressor genes and proto-oncogene in human colon cancer cell lines. World J Gastroenterol. 2003; 9(9):1976-80. PMC: 4656656. DOI: 10.3748/wjg.v9.i9.1976. View

17.

Tycko B . Epigenetic gene silencing in cancer. J Clin Invest. 2000; 105(4):401-7. PMC: 289180. DOI: 10.1172/JCI9462. View

18.

Esteller M, Hamilton S, Burger P, Baylin S, Herman J . Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999; 59(4):793-7. View

19.

Siegfried Z, Cedar H . DNA methylation: a molecular lock. Curr Biol. 1997; 7(5):R305-7. DOI: 10.1016/s0960-9822(06)00144-8. View

20.

Toyota M, Ahuja N, Suzuki H, Itoh F, Imai K, Baylin S . Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res. 1999; 59(21):5438-42. View